Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dovitinib + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Allarity Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Dovitinib + paclitaxel is an investigational combination therapy consisting of dovitinib, a small molecule inhibitor of multiple receptor tyrosine kinases including fibroblast growth factor receptors (FGFR), vascular endothelial growth factor receptors (VEGFR), and platelet-derived growth factor receptors (PDGFR), and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Dovitinib acts by inhibiting signaling pathways involved in tumor cell proliferation and angiogenesis, while paclitaxel disrupts mitosis by stabilizing microtubules. Preclinical studies have shown that this combination has additive antitumor effects, particularly in gastric adenocarcinoma models, leading to greater tumor regression and improved survival compared to either agent alone[1][2]. The combination is being explored for its potential to enhance the efficacy of standard chemotherapy regimens.
- Other names
- Dovitinib lactate + Paclitaxel
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on dovitinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dovitinib + paclitaxel.